Loss-of-function variants of TREM2 increase the risk for Alzheimer’s disease (AD). A new study presents a therapeutic candidate, ATV:TREM2, a TREM2 activating antibody engineered with a transferrin receptor binding site to facilitating blood-to-brain transport. ATV:TREM2 treatment in AD model mice improved energy metabolism and microglial function.